Compare Summit Therapeutics Inc (SMMT) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Western Alliance Bancorporation — how do they compare? Summit Therapeutics Inc trades at $17.38 (market cap $13.71B), while Western Alliance Bancorporation trades at $74.43 (market cap $8.24B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.23% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Western Alliance Bancorporation for 3 Days on average.
| SMMT | WAL | |
|---|---|---|
Market Cap | $13.71B | $8.24B |
Volume | 6,173,057 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $26.38 | $96.08 |
52-Week Low | $12.43 | $66.70 |
Typical Hold Time | 16 Days | 3 Days |
Enterprise Value | $13.04B | $9.76B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Western Alliance Bancorporation (WAL) trades at $74.22, down 0.17% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.52 and net income margin of 25.43%, while recent earnings have mostly beaten expectations. The company launched WA VenueX, an institutional financial platform, signaling innovation in digital banking services. Analyst consensus is strongly bullish with a $84.33 price target, though technical indicators suggest near-term caution.
WAL presents a compelling value opportunity with attractive valuation multiples and solid profitability, but faces headwinds from bearish technical trends and interest rate sensitivity. The stock's upside hinges on continued earnings growth and successful execution of new initiatives like WA VenueX, while regulatory changes and economic conditions remain key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
